Department of Laboratory Medicine, University of Washington, Seattle, WA, United States.
Department of Laboratory Medicine, University of Washington, Seattle, WA, United States.
J Clin Virol. 2013 Dec;58 Suppl 1(0 1):e38-43. doi: 10.1016/j.jcv.2013.08.014. Epub 2013 Aug 26.
The ARCHITECT HIV Ag/Ab Combo assay has a wide dynamic range for determining the sample-to-cutoff ratio (S/CO) values compared to other diagnostic HIV antibody assays.
Determine the performance of an HIV testing algorithm that uses the ARCHITECT combo assay in the clinical setting and explore the utility of the signal-to-cutoff (S/CO) ratio to predict acute HIV-1 infection status.
A retrospective analysis of clinical samples from a hospital and referral population screened for HIV-1 infection between May 2011 and March 2013. Repeatedly reactive samples were tested using the Multispot HIV-1/HIV-2 rapid test and depending on that result, confirmatory orthogonal testing used the Western blot (WB) for HIV-1, Immunoblot for HIV-2 and nucleic acid amplification testing (NAAT) for HIV RNA.
A total of 21,317 test results were evaluated of which 509 were ARCHITECT repeatedly reactive; of these, 422 were Multispot-reactive only for HIV-1 (413 WB-positive; 9 indeterminate), 4 were Multispot-reactive for both HIV-1 and HIV-2 (one HIV-2 immunoblot-positive with 17 HIV-2 RNA copies/mL) and 83 were Multispot-non-reactive of which 15 were HIV-1 RNA positive and represented acute HIV-1 infection. There was an association among the ARCHITECT S/CO (median; IQR) values for antibody-negative (0.14; 0.11-0.16), acute infection (33; 2.1-76) and established HIV-1 infection (794; 494-1,029) (Kruskal-Wallis, p<0.0001).
The ARCHITECT combo assay with Multispot confirmation and reserved use of HIV-1 WB, HIV-2 Immunoblot and HIV NAAT for Multispot dual HIV-1/2 infection, and NAAT alone for Multispot-negative specimens, had a suitable test performance for detecting acute and established HIV infection.
ARCHITECT HIV Ag/Ab Combo 检测试剂与其他诊断 HIV 抗体检测试剂相比,具有更宽的测定样本/临界值(S/CO)比值的动态范围。
确定在临床环境中使用 ARCHITECT 组合检测试剂的 HIV 检测算法的性能,并探索信号/临界值(S/CO)比值在预测急性 HIV-1 感染状态方面的应用。
对 2011 年 5 月至 2013 年 3 月期间筛查 HIV-1 感染的医院和转诊人群的临床样本进行回顾性分析。对反复出现反应的样本使用 Multispot HIV-1/HIV-2 快速检测进行检测,根据检测结果,使用 Western blot(WB)检测 HIV-1、免疫印迹检测 HIV-2 和核酸扩增检测(NAAT)检测 HIV RNA 进行确证性正交检测。
共评估了 21317 次检测结果,其中 509 次为 ARCHITECT 反复出现反应;其中,422 次仅为 Multispot 检测 HIV-1 反应阳性(413 次 WB 阳性;9 次不确定),4 次为 Multispot 检测 HIV-1 和 HIV-2 均反应阳性(1 次 HIV-2 免疫印迹阳性,HIV-2 RNA 拷贝/ml 为 17),83 次为 Multispot 检测阴性,其中 15 次 HIV-1 RNA 阳性,代表急性 HIV-1 感染。ARCHITECT 抗体阴性(中位数;四分位数间距)的 S/CO 值(0.14;0.11-0.16)、急性感染(33;2.1-76)和已建立的 HIV-1 感染(794;494-1029)之间存在相关性(Kruskal-Wallis,p<0.0001)。
ARCHITECT 组合检测试剂结合 Multispot 确证,保留用于 Multispot 双重 HIV-1/2 感染的 HIV-1 WB、HIV-2 免疫印迹和 HIV NAAT,以及单独用于 Multispot 阴性标本的 HIV NAAT,在检测急性和已建立的 HIV 感染方面具有合适的检测性能。